The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. (Q43574806)

24 November 2017

title

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. (English)

1 reference

24 November 2017

Sean Emery

0 references

Jens D Lundgren

0 references

H Clifford Lane

1 reference

24 November 2017

Donald I Abrams

1 reference

24 November 2017

David A Cooper

1 reference

24 November 2017

Janet H Darbyshire

1 reference

24 November 2017

James D Neaton

1 reference

24 November 2017

ESPRIT Study Group

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Contemporary Clinical Trials

24 November 2017

published in

1 reference

24 November 2017

1 reference

24 November 2017

1 reference

24 November 2017

page(s)

198-220

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

AIDS at a university hospital in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Sample size calculation for complex clinical trials with survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900179-9

7 January 2021

10.1016/S0197-2456(01)00179-9

Identifiers

DOI

1 reference

24 November 2017

1 reference